Generation of 5 and 17 kDa human growth hormone fragments through limited proteolysis

Growth Factors

Volumn 27, Issue 5, 2009, Pages 255-264

  Such Sanmartín, Gerard ^a   Bosch, Jaume ^a   Segura, Jordi ^a,b   Gutiérrez Gallego, Ricardo ^a,b  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

HGH1 43; HGH44 191; Human growth hormone fragments; Limited proteolysis; Protein structure; Thermolysin

Indexed keywords

HUMAN GROWTH HORMONE; ISOPROTEIN; PEPSIN A; PROTEINASE; PROTEINASE K; THERMOLYSIN; TRYPSIN;

AMINO ACID SEQUENCE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CROSS REACTION; DISULFIDE BOND; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; FEASIBILITY STUDY; HUMAN; IMMUNOASSAY; INCUBATION TIME; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PH; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN PURIFICATION; PROTEIN TARGETING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SURFACE PLASMON RESONANCE;

HUMAN GROWTH HORMONE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOASSAY; PEPSIN A; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURFACE PLASMON RESONANCE; THERMOLYSIN; TRYPSIN;

EID: 70349422262     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.1080/08977190903110121     Document Type: Article

References (41)

1. Alam KS, Morimoto M, Yoshizato H, Fujikawa T, Furukawa K, Tanaka M, Nakashima K. 1998. Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro. J Biotechnol 65:183-190.
2. Albertsson-Wikland K, Jansson C, Rosberg S, Novamo A. 1993. Time-resolved immunofluorometric assay of human growth hormone. Clin Chem 39:1620-1625.
3. Baumann G. 1999. Growth hormone heterogeneity in human pituitary and plasma. Horm Res 51(Suppl. 1):2-6.
4. Bidlingmaier M, Suhr J, Ernst A, Wu Z, Keller A, Strasburger CJ, Bergmann A. 2009. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin Chem 55:445-453.
5. Boguszewski CL, Hynsjo L, Johannsson G, Bengtsson BA, Carlsson LM. 1996. 22-kD Growth hormone exclusion assay: A new approach to measurement of non-22-kD growth hormone isoforms in human blood. Eur J Endocrinol 135:573-582.
6. Chantalat L, JonesN, Korber F, Navaza J, Pavlovsky AG. 1995. The crystal structure of wild-type growth hormone at 2.5Á resolution. Prot Pep Lett 2:333-340.
7. de Vos AM, Ultsch M, Kossiakoff AA. 1992. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 255:306-312.
8. de Vos AM, Toma S, Kossiakoff AA. 1995. Human growth hormone by limited proteolysis. Science 45:306-312.
9. Duda KM, Brooks CL. 2003. Identification of residues outside the two binding sites that are critical for activation of the lactogenic activity of human growth hormone. J Biol Chem 278: 22734-22739.
10. Fontana A, de Laureto PP, Spolaore B, Fontana A. 2004a. Limited proteolysis. Biochemistry 51:299-321.
11. Fontana A, de Laureto PP, Spolaore B, Frare E, Picotti P, Zambonin M. 2004b. Probing protein structure by limited proteolysis. Acta Biochim Pol 51:299-321.
12. Frigeri LG, Teguh C, Ling N,Wolff GL, Lewis UJ. 1988. Increased sensitivity of adipose tissue to insulin after in vivo treatment of yellow Avy/A obese mice with amino-terminal peptides of human growth hormone. Endocrinology 122:2940-2945.
13. Ge G, Fernandez CA, Moses MA, Greenspan DS. 2007. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci USA 104: 10010-10015.
14. Graf L, Li CH, Jibson MD. 1982. Human somatotropin. Selective removal with trypsin of residues 135-145 from the hormone molecule with no loss of biological activities. J Biol Chem 257:2365-2369.
15. Graf L, Li CH, Jibson MD. 1992. Human growth hormone molecule with no loss of the complex. Science 255:306-312.
16. Haro LS, Singh RN, Lewis UJ, Martinez AO, Galosy SS, Staten NR, Krivi GG. 1996. Human growth hormone deletion mutant (hGH44-191) binds with high affinity to lactogenic receptors but not to somatogenic receptors. Biochem Biophys Res Commun 222:421-426.
17. Hettiarachchi M, Watkinson A, Leung KC, Sinha YN, Ho KK, Kraegen EW. 1997. Human growth hormone fragment (hGH44-91) produces insulin resistance and hyperinsulinemia but is less potent than 22 kDa hGH in the rat. Endocrine 6:47-52.
18. Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson-Wikland K. 1997. Growth hormone (GH) assays: Influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin Chem 43:950-956.
19. Kasimova MR, Kristensen SM, Howe PW, Christensen T, Matthiesen F, Petersen J, Sorensen HH, Led JJ. 2002. NMR studies of the backbone flexibility and structure of human growth hormone: A comparison of high and low pH conformations. J Mol Biol 318:679-695.
20. Kohler M, Puschel K, Sakharov D, Tonevitskiy A, Schanzer W, Thevis M. 2008. Detection of recombinant growth hormone in human plasma by a 2-D PAGE method. Electrophoresis 29:4495-4502.
21. Kohler M, Thomas A, Puschel K, Schanzer W, Thevis M. 2009. Identification of human pituitary growth hormone variants by mass spectrometry. J Proteome Res 8:1071-1076.
22. Komatsu N, Saijoh K, Otsuki N, Kishi T, Micheal IP, Obiezu CV, Borgono CA, Takehara K, Jayakumar A, Wu HK, Clayman GL, Diamandis EP. 2007. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. Clin Chim Acta 377:228-236.
23. Lecomte CM, Renard A, Martial JA. 1987. A new natural hGH variant-17.5 kd-produced by alternative splicing. An additional consensus sequence which might play a role in branchpoint selection. Nucleic Acids Res 15:6331-6348.
24. Lewis UJ, Lewis LJ, Salem MA, Staten NR, Galosy SS, Krivi GG. 1991. A recombinant-DNA-derived modification of human growth hormone (hGH44-191) with enhanced diabetogenic activity. Mol Cell Endocrinol 78:45-54.
25. Lewis UJ, Sinha YN, Lewis GP. 2000. Structure and properties of members of the hGH family: A review. Endocr J 47(Suppl.): S1-S8.
26. Lopez-Guajardo CC, Armstrong LS, Jordan L, Staten NR, Krivi GG, Martinez AO, Haro LS. 1998. Generation, characterization and utilization of anti-human growth hormone 1-43, (hGH1-43), monoclonal antibodies in an ELISA. J Immunol Methods 215:179-185.
27. Palmetshofer A, Zechner D, Luger TA, Barta A. 1995. Splicing variants of the human growth hormone mRNA: Detection in pituitary, mononuclear cells and dermal fibroblasts. Mol Cell Endocrinol 113:225-234.
28. Peterson FC, Brooks CL. 2004. Different elements of mini-helix 1 are required for human growth hormone or prolactin action via the prolactin receptor. Protein Eng Des Sel 17:417-424.
29. Polverino dL, Toma S, Tonon G, Fontana A. 1995. Probing the structure of human growth hormone by limited proteolysis. Int J Pept Protein Res 45:200-208.
30. Rowlinson SW, Waters MJ, Lewis UJ, Barnard R. 1996. Human growth hormone fragments 1-43 and 44-191: In vitro somatogenic activity and receptor binding characteristics in human and nonprimate systems. Endocrinology 137:90-95.
31. Salem MA. 1988. Effects of the amino-terminal portion of human growth hormone on glucose clearance and metabolism in normal, diabetic, hypophysectomized, and diabetic-hypophysectomized rats. Endocrinology 123:1565-1576.
32. Salem MA, Wolff GL. 1989. Potentiation of response to insulin and anti-insulin action by two human pituitary peptides in lean agouti A/a, obese yellow Avy/A, and C57BL/6J-ob/ob mice. Proc Soc Exp Biol Med 191:113-123.
33. Shimizu T, Murakami Y, Nishiki M, Koshimura K, Oki Y, Kato Y. 2004. Contents and release of human growth hormone1-43 (hGH1-43) in human pituitary glands and hGH-producing pituitary adenoma cells. Biomed Res 25:141-146.
34. Sinha YN, Jacobsen BP. 1994. Human growth hormone (hGH)-(44-191), a reportedly diabetogenic fragment of hGH, circulates in human blood: Measurement by radioimmunoassay. J Clin Endocrinol Metab 78:1411-1418.
35. Spolaore B, Polverino dL, Zambonin M, Fontana A. 2004. Limited proteolysis of human growth hormone at low pH: Isolation, characterization, and complementation of the two biologically relevant fragments 1-44 and 45-191. Biochemistry 43: 6576-6586.
36. Such-Sanmartín G, Bosch J, Segura J, Wu M, Du H, Chen G, Wang S, Vila-Perello M, Andreu D, Gutiérrez-Gallego R. 2008. Characterisation of the 5 kDa growth hormone isoform. Growth Factors 26:152-162.
37. Tsushima T, Katoh Y, Miyachi Y, Chihara K, Teramoto A, Irie M, Hashimoto Y. 1999. Serum concentration of 20K human growth hormone (20K hGH) measured by a specific enzyme-linked immunosorbent assay. Study Group of 20K hGH. J Clin Endocrinol Metab 84:317-322.
38. Warner MD, Sinha YN, Peabody CA. 1993. Growth hormone and prolactin variants in normal subjects. Relative proportions in morning and afternoon samples. HormMetab Res 25:425-429.
39. Wroblewski VJ, Kaiser RE, Becker GW. 1993. Proteolysis of human growth hormone by rat thyroid gland in vitro: Application of electrospray mass spectrometry and N-terminal sequencing to elucidate a metabolic pathway. Pharm Res 10:1106-1114.
40. Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. 1999. Detection of doping with human growth hormone. Lancet 353:895.
41. Zhan X, Giorgianni F, Desiderio DM. 2005. Proteomics analysis of growth hormone isoforms in the human pituitary. Proteomics 5:1228-1241.